Cell Growth & Differentiation, Vol 9, Issue 1 71-78, Copyright © 1998 by American Association of Cancer Research

ARTICLES

Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I

PY d'Avis, SC Robertson, AN Meyer, WM Bardwell, MK Webster and DJ Donoghue
Department of Chemistry and Biochemistry, Center for Molecular Genetics, University of California at San Diego, La Jolla 92093-0367, USA.

Thanatophoric dysplasia type I (TDI) is a neonatal lethal skeletal dysplasia caused by several mutations in the extracellular domain of fibroblast growth factor receptor 3. These mutations occur either in the Ig2-Ig3 linker domain or in the extracellular juxtamembrane domain, and all involve mutation of the wild-type residue to Cys. In all cases, the presence of the mutant Cys residue allows the receptor to dimerize abnormally, resulting in ligand-independent activation. This is also manifested by increased biological signaling, increased tyrosine phosphorylation, and in vitro kinase activity associated with dimeric receptors. These results suggest that TDI is caused by Cys-mediated intermolecular disulfide bonding, leading to constitutive receptor activation as a result of these mutations. Mutations causing TDI are discussed with respect to activating mutations in other receptors that are implicated in human disease.

This article has been cited by other articles:

				J. E. Ruhe, S. Streit, S. Hart, C.-H. Wong, K. Specht, P. Knyazev, T. Knyazeva, L. S. Tay, H. L. Loo, P. Foo, et al. Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines Cancer Res., December 1, 2007; 67(23): 11368 - 11376. [Abstract] [Full Text] [PDF]

				T. Thyagarajan, S. Totey, M. J. S. Danton, and A. B. Kulkarni GENETICALLY ALTERED MOUSE MODELS: THE GOOD, THE BAD, ANDTHE UGLY Crit. Rev. Oral. Biol. Med., May 1, 2003; 14(3): 154 - 174. [Abstract] [Full Text] [PDF]

				D. J. Penington, I. Bryant, and D. J. Riese II Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities Cell Growth Differ., June 1, 2002; 13(6): 247 - 256. [Abstract] [Full Text] [PDF]

				T. Iwata, C.-L. Li, C.-X. Deng, and C. A. Francomano Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice Hum. Mol. Genet., June 1, 2001; 10(12): 1255 - 1264. [Abstract] [Full Text] [PDF]

				L. Chen, C. Li, W. Qiao, X. Xu, and C. Deng A Ser365{->}Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia Hum. Mol. Genet., March 1, 2001; 10(5): 457 - 465. [Abstract] [Full Text] [PDF]

				C. A. Bell, J. A. Tynan, K. C. Hart, A. N. Meyer, S. C. Robertson, and D. J. Donoghue Rotational Coupling of the Transmembrane and Kinase Domains of the Neu Receptor Tyrosine Kinase Mol. Biol. Cell, October 1, 2000; 11(10): 3589 - 3599. [Abstract] [Full Text]

				L. Frederick, X.-Y. Wang, G. Eley, and C. D. James Diversity and Frequency of Epidermal Growth Factor Receptor Mutations in Human Glioblastomas Cancer Res., March 1, 2000; 60(5): 1383 - 1387. [Abstract] [Full Text]

				M. L. Lux, B. P. Rubin, T. L. Biase, C.-J. Chen, T. Maclure, G. Demetri, S. Xiao, S. Singer, C. D.M. Fletcher, and J. A. Fletcher KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors Am. J. Pathol., March 1, 2000; 156(3): 791 - 795. [Abstract] [Full Text] [PDF]

				J. Labrecque, N. Mc Nicoll, M. Marquis, and A. De Lean A Disulfide-bridged Mutant of Natriuretic Peptide Receptor-A Displays Constitutive Activity. ROLE OF RECEPTOR DIMERIZATION IN SIGNAL TRANSDUCTION J. Biol. Chem., April 2, 1999; 274(14): 9752 - 9759. [Abstract] [Full Text] [PDF]

				N. S. Fracchiolla, S. Luminari, L. Baldini, L. Lombardi, A. T. Maiolo, and A. Neri FGFR3 Gene Mutations Associated With Human Skeletal Disorders Occur Rarely in Multiple Myeloma Blood, October 15, 1998; 92(8): 2987 - 2989. [Full Text] [PDF]